In the LEO Foundation, we take a long-term view on creating value and impact through active ownership, philanthropic activities and investments.
- The aim of our active ownership of LEO Pharma is for the company to develop as a global leader in dermatology, delivering outstanding results
- We will support the best international research in skin diseases and make Denmark a global beacon for skin research
- We will grow our financial assets by generating attractive returns supporting our active ownership of LEO Pharma and our philanthropic purpose
The LEO Foundation is the sole owner of LEO Pharma. Founded in 1908, LEO Pharma develops, manufactures and sells pharmaceutical drugs globally to patients suffering from skin diseases. LEO Pharma’s vision is to become the preferred dermatology care partner improving people’s lives around the world. To realise this vision, the company is expanding its market footprint with acquisitions and development of new drugs and therapies that address unmet medical needs.
LEO Pharma has its own sales forces in 61 countries and employs around 5,000 employees worldwide.
The LEO Foundation exercises active and ambitious ownership of LEO Pharma as part of our efforts to ensure the company’s ongoing development as an independent, competitive and research-based pharmaceutical company. The aim is for the company to develop as a global leader in dermatology, delivering outstanding results.
As part of the LEO Foundation’s active ownership, we elect the board of directors of LEO Pharma and approve the company’s long-term performance targets.
For more information: www.leo-pharma.com
The largest human organ is the skin. At any point in time one in every four persons will suffer from a skin disease, which is often visible and stigmatizing – and in some cases completely debilitating. Therefore, much more research in skin and skin diseases is required – in order to provide better diagnoses, treatments and perhaps even cures for the millions of people living with skin diseases.
Through our LEO Foundation grants and awards we want to make an impact and the aim of our philanthropic activities is to support the best dermatology research worldwide and make Denmark a global beacon for skin research.
LEO Foundation has approximately DKK 18 billion invested in financial assets. The main objectives of the investments are to ensure continued financial capability to support LEO Pharma’s long-term continuation and strategic development, as well as provide funds for the LEO Foundation’s philanthropic activities. In line with these objectives, we strive to generate the best possible returns while retaining a sensible, well-balanced risk profile.